ALTEROLA BIOTECH INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Audited consolidated statement of cash flows

In millions of USD, except per-share amounts

	FY2024 12 months to Mar 31, 2024	FY2023 12 months to Mar 31, 2023	FY2022 12 months to Mar 31, 2022	FY2021 12 months to Sep 30, 2020	FY2019 12 months to Sep 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period
Shares issued for services
Deferred tax asset
Non cash currency adjustments
Changes in assets and liabilities:
Stock based compensation
Funds in attorney trust
Receivables
Inventory
VAT receivable
Deferred tax asset
Accounts payable
Accrued liabilities
Increase (decrease) in accrued interest
Increase (decrease) in advance from related party
Increase (decrease) in due from attorney
Net Cash Used in Operating Activities
Acquisition of intellectual property
Website development
Investment in intellectual property
Net Cash Used by Investing Activities
Proceeds from share issuance
Convertible debt issuance
Loan from related parties
Net Cash Provided by Financing Activities
Net Increase (Decrease) in Cash and Cash Equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Effect of exchange rate adjustments on cash
Net change in cash

Foreign currency change
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
SUPPLEMENTAL CASH FLOW INFORMATION
Interest paid
Income taxes paid
NON-CASH INVESTING AND FINANCING INFORMATION
Prepaid stock compensation
C2 Wellness acquisition – shares issued
Return of intangible assets
Impairment of deferred tax asset
Impairment of intangible assets

Gain on debt conversion
Shares issued for conversion of debt

Comments